Skip to Main Content

Author Details

Tamara L Lotan
Johns Hopkins University School of Medicine
2006
191
48
PMIDPaper TitleJournal TitlePublished Year
37907729Prognostic and therapeutic potential of senescent stromal fibroblasts in prostate cancer.Nat Rev Urol2024
34969655p53 Immunohistochemistry to Identify Very High-risk Primary Prostate Cancer: A Prospective Cohort Study with Three Decades of Follow-up.Eur Urol Oncol2023
37856213Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw2023
37661807Positive GPNMB Immunostaining Differentiates Renal Cell Carcinoma With Fibromyomatous Stroma Associated With TSC1/2/MTOR Alterations From Others.Am J Surg Pathol2023
35568781High intratumoral plasma cells content in primary prostate cancer defines a subset of tumors with potential susceptibility to immune-based treatments.Prostate Cancer Prostatic Dis2023
37060201A novel prostate cancer subtyping classifier based on luminal and basal phenotypes.Cancer2023
37249585Associations between Etiologic or Prognostic Tumor Tissue Markers and Neighborhood Contextual Factors in Male Health Professionals Diagnosed with Prostate Cancer.Cancer Epidemiol Biomarkers Prev2023
37345735Somatic loss of ATM is a late event in pancreatic tumorigenesis.J Pathol2023
37012549Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial.Nat Med2023
37173210Clinical and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate Cancer.Eur Urol2023
37307876Predicting Prostate Cancer Molecular Subtype With Deep Learning on Histopathologic Images.Mod Pathol2023
36972661Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers.Eur J Cancer2023
37331435Collagen VI deposition mediates stromal T cell trapping through inhibition of T cell motility in the prostate tumor microenvironment.Matrix Biol2023
37164128Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer.Ann Oncol2023
37196219MLH1 Loss in Primary Prostate Cancer.JCO Precis Oncol2023
36752203Association of self-identified race and genetic ancestry with the immunogenomic landscape of primary prostate cancer.JCI Insight2023
36828362ERG Status at the Margin Is Associated With Biochemical Recurrence After Radical Prostatectomy With Positive Surgical Margins.Mod Pathol2023
36798177Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial.Res Sq2023
36894369Reprint of: de novo neuroendocrine features in prostate cancer.Hum Pathol2023
36367998Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial.J Clin Oncol2023
36125519Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions.Mol Cancer Res2023
34226663A transcriptomic model for homologous recombination deficiency in prostate cancer.Prostate Cancer Prostatic Dis2022
35836303The prostate tissue-based telomere biomarker as a prognostic tool for metastasis and death from prostate cancer after prostatectomy.J Pathol Clin Res2022
35810832De novo neuroendocrine features in prostate cancer.Hum Pathol2022
36509074NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023.J Natl Compr Canc Netw2022
35941720Xanthomatous Giant Cell Renal Cell Carcinoma: Another Morphologic Form of TSC -associated Renal Cell Carcinoma.Am J Surg Pathol2022
36001857Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials.J Clin Oncol2022
35971807Localization of macrophage subtypes and neutrophils in the prostate tumor microenvironment and their association with prostate cancer racial disparities.Prostate2022
36309296Clonal relationships of adjacent Gleason pattern 3 and Gleason pattern 5 lesions in Gleason Scores 3+5=8 and 5+3=8.Hum Pathol2022
35968526Prostate multi-parametric magnetic resonance imaging appearance of diffuse adenosis of the peripheral zone (DAPZ).Urol Case Rep2022
36357396An mTORC1-mediated negative feedback loop constrains amino acid-induced FLCN-Rag activation in renal cells with TSC2 loss.Nat Commun2022
35072947GPNMB expression identifies TSC1/2/mTOR-associated and MiT family translocation-driven renal neoplasms.J Pathol2022
35013522Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics.Prostate Cancer Prostatic Dis2022
35082164Antizyme Inhibitor 1 Regulates Matrikine Expression and Enhances the Metastatic Potential of Aggressive Primary Prostate Cancer.Mol Cancer Res2022
35333400Association of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer.Cancer2022
35104804Health inequity drives disease biology to create disparities in prostate cancer outcomes.J Clin Invest2022
34864149Validation of Long Mononucleotide Repeat Markers for Detection of Microsatellite Instability.J Mol Diagn2022
34783071Clinical and genomic features of SPOP-mutant prostate cancer.Prostate2022
34652816P2X4 purinergic receptors offer a therapeutic target for aggressive prostate cancer.J Pathol2022
34533610Association between pathogenic germline mutations in BRCA2 and ATM and tumor-infiltrating lymphocytes in primary prostate cancer.Cancer Immunol Immunother2022
34049847Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma.Eur Urol Oncol2022
32948433Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey.Urol Oncol2021
33795875A PRC2-independent function for EZH2 in regulating rRNA 2'-O methylation and IRES-dependent translation.Nat Cell Biol2021
33626496Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer.Eur J Cancer2021
33600062A distinct repertoire of cancer-associated fibroblasts is enriched in cribriform prostate cancer.J Pathol Clin Res2021
33568675Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes.Nat Commun2021
33785256Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy.Eur Urol2021
34939926Extent, impact, and mitigation of batch effects in tumor biomarker studies using tissue microarrays.Elife2021
34431104Reciprocal YAP1 loss and INSM1 expression in neuroendocrine prostate cancer.J Pathol2021
34062284Assessment of MYC/PTEN Status by Gene-Protein Assay in Grade Group 2 Prostate Biopsies.J Mol Diagn2021
  • 1 - 50 of 191

Recommended Authors

Michael Sigouros
Caryl and Israel Englander Institute for Precision Medicine
Career Start Year 2017
Number of shared co-authors 28
Wei Yuan
The Institute for Cancer Research
Career Start Year 2015
Number of shared co-authors 26
Jacqueline Fontugne
Institut Curie, CNRS, PSL Research University
Career Start Year 2013
Number of shared co-authors 23
Martina Kluth
Institute of Pathology, University Medical Center Hamburg-Eppendorf
Career Start Year 2012
Number of shared co-authors 6
Steven Hazell
Royal Marsden NHS Foundation Trust
Career Start Year 2011
Number of shared co-authors 4
Kyung Park
New York University Langone Health
Career Start Year 2010
Number of shared co-authors 30
Theresa Y MacDonald
Caryl and Israel Englander Institute for Precision Medicine
Career Start Year 2010
Number of shared co-authors 35
Susana Miranda
The Institute of Cancer Research
Career Start Year 2008
Number of shared co-authors 40
Robert J Lonigro
Michigan Center for Translational Pathology, University of Michigan ann arbor
Career Start Year 2007
Number of shared co-authors 45
Verena Sailer
Institute for Pathology, University Hospital Schleswig-Holstein
Career Start Year 2007
Number of shared co-authors 29
Mark M Pomerantz
Dana-Farber Cancer Institute
Career Start Year 2007
Number of shared co-authors 56
Mitchell G Lawrence
Biomedicine Discovery Institute, Monash University
Career Start Year 2005
Number of shared co-authors 9
Alok K Tewari
Dana-Farber Cancer Institute, Harvard Medical School
Career Start Year 2005
Number of shared co-authors 6
Nening Dennis
Institute of Cancer Research
Career Start Year 2004
Number of shared co-authors 4
Anne Y Warren
Cambridge University Hospitals National Health Service Foundation Trust
Career Start Year 2003
Number of shared co-authors 20
Adam Foye
University of California San Francisco
Career Start Year 2003
Number of shared co-authors 28
Wassim Abida
Memorial Sloan Kettering Cancer Center
Career Start Year 2002
Number of shared co-authors 71
Michael Fraser
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2001
Number of shared co-authors 47
Joshi J Alumkal
Rogel Cancer Center, University of Michigan ann arbor
Career Start Year 1999
Number of shared co-authors 62
Xuhong Cao
Michigan Center for Translational Pathology.
Career Start Year 1999
Number of shared co-authors 50
Hayley C Whitaker
University College London
Career Start Year 1999
Number of shared co-authors 9
Geert J L H van Leenders
Erasmus MC Cancer Institute, University Medical Center
Career Start Year 1998
Number of shared co-authors 18
Phillip G Febbo
Illumina Inc.
Career Start Year 1997
Number of shared co-authors 40
Claudia Hube-Magg
Institute of Pathology, University Medical Center Hamburg-Eppendorf
Career Start Year 1997
Number of shared co-authors 6
Andrew J Evans
Princess Margaret Cancer Center, University Health Network.
Career Start Year 1996
Number of shared co-authors 22
Nallasivam Palanisamy
Vattikuti Urology Institute
Career Start Year 1990
Number of shared co-authors 30
Gyorgy Petrovics
Henry Jackson Foundation for the Advancement of Military Medicine (HJF)
Career Start Year 1990
Number of shared co-authors 23
Tapio Visakorpi
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 1987
Number of shared co-authors 41
Dominique Trudel
Institut du cancer de Montreal
Career Start Year 1985
Number of shared co-authors 21
George Steven Bova
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 1982
Number of shared co-authors 35

Collaborators

Emmanuel S Antonarakis
The Sidney Kimmel Cancer Comprehensive Cancer Center at Johns Hopkins
Co-authored papers 33
Edward M Schaeffer
Northwestern University Feinberg School of Medicine
Co-authored papers 33
Elai Davicioni
Veracyte Inc.
Co-authored papers 24
Ashley E Ross
Northwestern University
Co-authored papers 22
William B Isaacs
The Brady Urological Institute, The Johns Hopkins School of Medicine
Co-authored papers 19
Jeffrey J Tosoian
Vanderbilt University Medical Center
Co-authored papers 18
Michael C Haffner
Fred Hutchinson Cancer Center
Co-authored papers 18
Daniel E Spratt
University Hospitals Seidman Cancer Center, Case Western Reserve University
Co-authored papers 14
Felix Y Feng
UCSF Medical Center-Mount Zion
Co-authored papers 14
Mohammed Alshalalfa
University of Miami Miller School of Medicine/Sylvester Comprehensive Cancer Center
Co-authored papers 14
Srinivasan Yegnasubramanian
Johns Hopkins University School of Medicine
Co-authored papers 13
Colin C Pritchard
University of Washington, USA Brotman Baty Institute for Precision Medicine
Co-authored papers 12
Bruce J Trock
Johns Hopkins University School of Medicine
Co-authored papers 11
Robert Jeffrey Karnes
Mayo Clinic
Co-authored papers 11
Mario A Eisenberger
Johns Hopkins University
Co-authored papers 10
Lorelei A Mucci
Co-authored papers 10
Scott A Tomlins
Rogel Cancer Center, University of Michigan Medical School ann arbor
Co-authored papers 9
Kenneth J Pienta
The Brady Urological Institute, Johns Hopkins University School of Medicine
Co-authored papers 9
Mark A Rubin
University of Bern
Co-authored papers 9
Yang Liu
Veracyte inc.
Co-authored papers 8
Pedro Isaacsson Velho
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins
Co-authored papers 8
Michael A Carducci
Johns Hopkins School of Medicine
Co-authored papers 8
Phuoc T Tran
University of Maryland School of Medicine
Co-authored papers 8
Robert B Den
Thomas Jefferson University Hospital
Co-authored papers 8
Rohit Mehra
Michigan Center for Translational Pathology.
Co-authored papers 8
Massimo Loda
Weill Medical College of Cornell University
Co-authored papers 8
Matthew P Deek
Rutgers Robert Wood Johnson Medical School, Rutgers University
Co-authored papers 7
Pedram Argani
The Johns Hopkins Hospital
Co-authored papers 7
Nicholas Erho
GenomeDx Biosciences Inc.
Co-authored papers 7
Himisha Beltran
Dana-Farber Cancer Institute
Co-authored papers 7
Release 1.2